Daxor Co. (NASDAQ:DXR) Short Interest Update

Daxor Co. (NASDAQ:DXR) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 31st total of 8,400 shares. Based on an average daily trading volume, of 16,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.5% of the shares of the stock are short sold.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its stake in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent SEC filing. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Daxor Stock Performance

DXR stock traded up $0.07 during midday trading on Tuesday, hitting $7.85. 6,860 shares of the stock were exchanged, compared to its average volume of 5,256. The stock’s 50-day moving average price is $8.33 and its 200-day moving average price is $8.73. Daxor has a fifty-two week low of $7.19 and a fifty-two week high of $10.00.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.